However, in the context of cancer therapy, the application of STING agonists constitutes a short-term, high-dose treatment strategy capable of effectively initiating the tumor-immunity cycle and promoting tumor regression highlighting the necessity for further comprehensive research and consideration in the development of small-molecule STING agonists. Here, STING1 is linked to cancer.